Core Viewpoint - The article discusses the recent performance and valuation concerns of Dawi Technology (大位科技), particularly in the context of the booming computing power leasing sector, highlighting significant discrepancies between its valuation and industry averages [1][2]. Group 1: Company Performance - Dawi Technology's stock has experienced a strong rally, achieving a price of 13.86 CNY per share, marking a 93.58% increase year-to-date and a total market capitalization exceeding 20 billion CNY [1]. - The company has reported a significant deviation in its valuation metrics, with a rolling price-to-earnings (P/E) ratio of 428.01 and a price-to-book (P/B) ratio of 26.30, compared to the industry averages of 46.83 and 3.82, respectively [1][2]. Group 2: Business Operations - The company clarified that its computing power leasing business, which began in 2024, generated only 1,123.20 million CNY in revenue for the first three quarters, contributing a mere 3.59% to total revenue, indicating minimal impact on overall performance [2]. - Dawi Technology anticipates a net loss for 2025, projecting a net profit range of -250 million to -125 million CNY, with a non-recurring net profit forecast of -1.3 billion to -800 million CNY, indicating ongoing operational challenges [2]. Group 3: Project Developments - The Zhangbei data center project, previously misinterpreted as a new capacity for computing power leasing, is clarified to be a facility providing customized server rooms and related infrastructure, with limited revenue contribution expected in 2025 [2]. - The company emphasized that its core business remains focused on leasing standardized server rooms, cabinets, bandwidth, and IP addresses, with a reported revenue of 31.31 million CNY for the first three quarters of 2025, primarily from cabinet leasing [2].

Core Viewpoint - Estée Lauder has filed a lawsuit against Walmart for selling counterfeit products, including perfumes and skincare items from its brands, which has raised concerns among consumers about the authenticity of products purchased from Walmart [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the U.S. District Court for the Central District of California, accusing Walmart of trademark infringement and selling counterfeit goods [1]. - Estée Lauder claims that Walmart's website features products that closely resemble its own, leading to consumer confusion [1]. - The company has requested economic compensation and an injunction to prevent Walmart from selling the alleged counterfeit products [2]. Group 2: Consumer Reactions - Many consumers, particularly in China, have reported experiences of purchasing suspected counterfeit products from Walmart and Sam's Club [6][8]. - Some consumers expressed disbelief that a reputable retailer like Walmart could be involved in selling counterfeit goods, leading to a loss of trust in non-official purchasing channels [8]. Group 3: Impact on Estée Lauder - Estée Lauder's sales are significantly reliant on various distribution channels, including Walmart, and the presence of counterfeit products could negatively impact its revenue [10]. - The company reported a strong performance in its latest financial results, with a 6% increase in net sales, driven by its skincare and fragrance segments [7][11]. - The lawsuit highlights the potential risks posed by counterfeit products to brand reputation and sales, especially in overlapping markets with Walmart [10][11]. Group 4: Walmart's Position - Walmart has stated its zero-tolerance policy towards counterfeit products and plans to respond appropriately to the lawsuit [2]. - The retailer's business model relies on offering competitive prices through global sourcing, which may inadvertently facilitate the sale of counterfeit goods [8][11].

2月12日晚间，千里科技发布公告称，增设联席董事长一名，并提名赵明先生为公司第六届董事 会非独立董事候选人。根据公告信息，赵明曾任荣耀终端股份有限公司CEO，执掌荣耀品牌10 年。作为资深科技产业领袖，赵明拥有逾 25 年全球科技企业管理经验。结合多方消息猜测，赵 明加入千里科技后或将出任联席董事长。 千里科技是一家由传统汽车制造业转型而来的 AI 科技公司，目前由国内 AI 行业早期创业者 印奇出任董事长。在他的掌舵下，千里科技正在全力押注"AI+车"的核心赛道。加入千里科技 之后，赵明的核心任务或将是助其共同推动 AI 商业模式的闭环落地。 这一任命背后，折射出 AI 技术浪潮进入新阶段的深层逻辑：AI竞争已不局限于技术和愿景 的比拼，最终必须回归到产品与商业盈利。作为 AI 1 . 0 时代的创业者，印奇对此体会颇深。 随着以强悍商业落地能力著称的赵明加入，这家新晋的AI科技公司有望补上产品化与规模化 的关键"拼图"。印奇将更侧重于 AI 前沿技术的战略布局与研发方向，而赵明更擅长商业化战 略，重点是将 AI 能力转化为可持续的商业增长。 自2 0 2 5年1月离任荣耀 CEO 后，赵明的去向一度引发市 ...

记者丨雷若馨 编辑丨孙超逸 2月12日，21世纪经济报道记者获悉，影石创新Insta360再次出圈，在成功上市后第一年年会上， 其一次性奖励优秀员工5套商品 房。 影石创新正在无人机与智能影像赛道同步"扩张"。该次年会也成为今年国内科技企业年会上的"最豪"奖品之一。 据悉，其获奖者均为"90后"员工。 该公司表示，希望借此激励回馈员工付出，同时帮助员工扎根于此。 同时，影石创始人刘靖康在现场称，2026年公司新品数量将远超去年，并公开首款手持云台相机的双摄外观。 2月12日，影石创新（688775.SH）股价收报221.69元，微涨0.83%；总市值889亿元。 送房送车送黄金 影石创新在激励员工的方式上，往往"不走寻常路"。 往年，该公司年会就曾送出金条和名车而出圈。过去连续八年累计共送出33辆车，总价值超1000万。 今年，其最高奖励首次升级为5套湾区商品房，以回馈员工的杰出贡献。 据悉， 今年获奖者均为90后，平均年龄不到32岁， 其中一位入职不到两年的年轻员工穿着cos装上台领奖。 影石年会活动负责人表示， 获奖员工可从两个环境优美、配套完善的高品质小区中自由选择。 该房产这不仅是物质激励，更希望助 ...

二、微信账号"浮萍9419"、微博账号"乘风已归来"、快手账号"东东情感"等，以AI换脸、声音 克隆等方式，假冒运动员、演员、主持人、企业家等公众人物，发布不实言论，借此吸粉引 流，或未经授权，售卖AI生成的公众人物"送祝福""拜年"等视频，从中不当牟利。相关账号已 被依法依约处置。 三、抖音账号"巷子里的鱼""禾粟"、快手账号"朵姐正能量""小猪猪"等，发布AI生成的虚假火 灾现场图片、视频，恶意编造、炒作火灾事故，混淆视听，扰乱公共秩序。相关账号已被依法 依约处置。 四、哔哩哔哩账号"真难我知道"、抖音账号"小奥特曼大智慧"、百度账号"清崽影视"等，借AI 魔改未成年人喜爱的动画角色，制作刀切小马宝莉头部、奥特曼怀孕等视频，传播低俗惊悚、 下一步，网信部门将对无AI标识的虚假不实信息保持高压严管态势，发现即处置，严厉打击违 规行为。同时，也呼吁广大网络内容创作者按照相关规定主动添加AI标识，避免误导公众，共 同营造风清气正的网络环境。 近期，部分网络账号发布AI生成合成信息时，不添加AI标识，存在利用虚假不实内容欺骗误 导公众的问题，破坏网络生态，造成恶劣影响。网信部门督促网站平台深入排查整治，依法依 约 ...

家电巨头"扎堆"去泰国建厂，实际上背靠国产家电在泰国的强势市场地位。海尔已经连续四年 稳坐泰国空调"榜一"之位，美的的冰箱和微波炉在泰国是数一数二的存在，TCL已是泰国电视 市占率的第二大品牌。 以前泰国人的生活，基本是被日韩品牌填满的，但现在他们反而越来越离不开中国家电，以前 许多人以为"性价比"就是家电出海的最大利器，但在泰国实地调研、对话家电行业的工厂、销 售端负责人之后，会发现国产家电的核心竞争力有着丰富的维度：它是更具科技感也更懂本地 需求的产品设计，能让一台洗衣机在泰国卖出8万泰铢（约合1.8万人民币）的高单价；它是依 靠供应链和数字工厂高效运转带来的成本管理优势；它是细致到考究产品标语如何贴、TikTok 短视频转化率的极致营销方法论…… 记者丨赖镇桃 编辑丨和佳 这几年，中国家电企业纷纷在泰国落点"最大"工厂。 2025年7月，海信集团海外最大生产基地——泰国HHA智能制造工业园奠基仪式举行。去年9 月，海尔泰国春武里空调工业园正式投产，这是中国品牌在东南亚地区规模最大的空调制造基 地。去年10月，TCL旗下的奥马冰箱得到泰国投资促进委员会（BOI）的批准在泰国建生产基 地，还有2022年已正 ...

Core Viewpoint - The National Healthcare Security Administration (NHSA) is set to adjust the National Medical Insurance Drug List in 2026, focusing on optimizing the review process and ensuring alignment with the current healthcare fund's payment capacity and drug supply situation [1][7]. Group 1: Drug List Adjustment Principles - The adjustment will adhere to the principles of steady progress and continuous optimization, emphasizing transparency and scientific evaluation in the review process [1][5]. - Traditional Chinese medicine (TCM) products with unclear adverse reactions will be prioritized for removal from the list [1][7]. Group 2: Reference Drug Communication Method - The NHSA has introduced a trial method for reference drug communication, which will allow for the selection of reference drugs to assess the value of new drug applications [3][5]. - This method aims to enhance the preparation of economic and clinical data by allowing early application for reference drug determination [5]. Group 3: Focus on Traditional Chinese Medicine - TCM products will be a key focus in the upcoming adjustments, particularly those with "unclear" labels in their instructions regarding contraindications and adverse reactions [5][7]. - From July 1, 2026, TCM products with unclear safety information will not be approved for re-registration, impacting those already on the list [5][11]. Group 4: Increase in Drug Applications - The number of drug applications for the National Medical Insurance Drug List has surged, with a projected increase of 30% to 40% in 2025 compared to 2024, and further growth expected in 2026 [6]. - The rapid approval of innovative drugs, with 76 new first-class innovative drugs approved in 2025, contributes to this increase [6]. Group 5: Regulatory Trends and Challenges - The tightening of regulations around TCM products indicates a rising barrier to entry, with a focus on eliminating products that lack clinical efficacy and have unclear safety profiles [11][12]. - The NHSA has been actively conducting price governance actions against TCM products that are overpriced without unique therapeutic effects, leading to their potential exclusion from reimbursement [12].

记者丨宋鹏 崔雯晴 邓志良 贺枫乔 邓晓俊 癌症从来不只是身体里的一个病灶，它是一场关于选择、尊严甚至是希望的全面考验。广州泰 和肿瘤医院院长钱朝南表示，曾有一项数据显示，十年前，一位肿瘤患者平均需拨打超过15个 电话，才能寻求到相对满意的治疗方案。这反映出肿瘤患者面临的首要挑战——信息的不对 称。 当一份肿瘤诊断书突如其来，患者与家庭面临的往往不仅是疾病本身，更是信息迷雾下的抉择 困境、对远期生活质量的忧虑以及先进治疗手段的可及性难题。在精准医学快速发展的今天， 理想的肿瘤治疗图景应是怎样？又如何将这幅图景变为每位患者可触及的现实？ 2025年12月，广州泰和肿瘤医院质子中心运营满一周年。这个华南首套质子治疗装置，在一年 内治疗了来自全球的550位患者，年龄跨度从13个月到91岁。但比技术突破更值得关注的，是 钱朝南和他团队正在推动的一场肿瘤治疗理念的深层变革。 "肿瘤治疗的目标，已从追求五年生存率，进化到追求有质量的长期生存。我们不仅要回答能 否治好，更要回答患者将如何生活。"广州泰和肿瘤医院院长钱朝南近日在接受岭南大医生主 理人宋鹏专访时表示，现代肿瘤治疗的深刻进化，在于其必须同步考量根治疾病与守护患者 ...

2025年，重庆、成都GDP分别高达3.38万亿和2.48万亿，分列全国第4和第7位；但存量独角兽企业仅10家和8家，位列全国第11、12位，被 GDP排名在两城之后的南京、合肥、武汉、天津反超。 一方面是耀眼的经济总量，一方面是略显黯淡的独角兽数量，重庆和成都的创新生态短板在哪里？2026年重庆两会"1号提案"直指痛点：高能 级创新平台支撑不足、龙头企业创新带动乏力、融合生态支撑效能仍有待加强。 记者丨杨期鑫 实习生郑凝 编辑丨蒋韵 不久前，《2025中国独角兽企业观察报告》发布，21城市观梳理创业邦旗下睿兽分析发布的2023—2025年《中国独角兽企业观察报告》（下简 称《报告》），一幅中国城市创新竞争力的"热力图"清晰展现。 2025年《报告》显示，中国现存509家独角兽企业，近八成密集扎堆在北京、上海、广东、江苏和浙江五地；从城市分布看，北京（120家）、 上海（98家） 的"创新双核"格局依然稳固，深圳（53家）、杭州（35家）、广州（26家）排名其后。 然而，21城市观注意到：对比2025年GDP前十强城市名单，GDP排名全国第4和第7的重庆、成都，却在独角兽企业数量前10城之外。取而代之 的，是 ...

2月10日， 2026年粤港澳大湾区灯会正式亮灯， 开启为期90日的光影盛宴！ 本届灯会以南沙天后宫景区、滨海公园为基础，"星河驰骋·骏马腾云""绿野仙踪·生态和鸣""逍遥天地·数智未来""千年一梦·烟火人间""同根同源·湾区 和韵"等五大展区将整个园区构建为一个完整的"梦幻奇境"。 以下是本次灯会的六大重磅玩法 将让大家从视觉、听觉、互动到味觉 全方位拉满体验感！ 亮点一： 绝美灯光秀 一眼值回票价 正式运营专属，打破传统赏灯模式 《南沙之夜·湾区之光》灯光秀 1000架次无人机表演 将光影科技与夜色完美融合 打造沉浸式灯光秀+无人机表演盛宴 欣赏传统灯会的温婉雅致 又有现代科技的震撼炫酷 每一秒都值得定格 随手一拍都是氛围感大片 亮点四：灯海中荡漾花香 打造广州年味天花板 赏灯之余，邂逅春日惊喜 园区内各类时令花卉同步绽放 灯影灼灼映花香 花香与灯韵交织 视觉与嗅觉双重享受 承包你新春的浪漫与温柔 亮点二：实景演艺+NPC互动 一秒穿越新春盛景 日日新鲜 一起周游互动 每日多场实景演艺轮番上演 NPC互动、情景舞剧、特色民俗巡游 可合影、可互动、可玩趣味小游戏 活人感、互动感直接拉满 沉浸式解锁新春限定惊 ...